

**ASX/Media Release**  
**31 August 2009**

**PRIMA BIOMED SECURES US FDA APPROVAL TO COMMENCE CVac™  
PHASE IIb CLINICAL TRIAL**

Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce that it has today received notification from the United States Food and Drug Administration (**FDA**) to commence its Phase IIb Clinical Trial for its headline product, the **CVac™** ovarian cancer vaccine treatment.

The Phase IIb trial will be conducted using 60 patients at the world-leading Fred Hutchinson Cancer Centre in Seattle in the USA, and will be managed by former Pfizer Director of Global Medical, Ms Ginny Raymond, who was recently appointed by Prima to the full-time position of Head of US Operations for the Company.

Prima plans to commence the trial in the near future and it signals another major step forward for the Company in its commercialisation pathway for the **CVac™** ovarian cancer vaccine treatment.

The trial will seek to add to the positive efficacy results from Prima's previous Phase IIa Trial which was conducted in Australia, on a significantly larger patient population.

Subject to the successful results of the Phase IIb Trial, the Company hopes to be in a position to then commence commercial scale treatment of ovarian cancer patients in Australia and New Zealand.

**CVac™** is a vaccine therapy treatment for ovarian cancer sufferers that is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer. There is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate, and there are currently no maintenance-based therapy products commercially available.

The Phase IIb Trial is designed to further confirm the ability of **CVac™** to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients.

Based on positive results from the trial, Prima plans to then embark on a final, Phase III, trial before securing FDA approval to market the product commercially into the global multi-billion dollar pharmacy oncology market.

Commenting on the clearance to commence the Phase IIb Trial, Prima BioMed executive director Martin Rogers said: "We are delighted to have received FDA clearance to commence our Phase IIb Trial for **CVac™**. This represents the culmination of years of hard work and commitment from our world class scientific team and is a testament to their ability and dedication the development of **CVac™**."

ENDS

**For further information please contact:**

Mr Martin Rogers  
Executive Director  
Prima BioMed  
Ph: 0428 268 357  
E: [martin.rogers@primabiomed.com.au](mailto:martin.rogers@primabiomed.com.au)

James Moses  
Investor and Media Relations  
Mandate Corporate  
Ph: 0420 991 574  
E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)

Website: [www.primabiomed.com.au](http://www.primabiomed.com.au)

**About CVac™ Ovarian Cancer Treatment**

**CVac™** is Prima BioMed's lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. **CVac™** is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US\$2.1b in 2007 and is expected to total US\$3.6b by 2010.

Regulatory approval and commercialisation of **CVac™** is the core focus for Prima.

**About Prima BioMed**

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.